Pharmacokinetics of a losartan potassium released from a transdermal therapeutic system for the treatment of hypertension

被引：7

作者：

Shams, M. S. ^{[1
]}

Alam, M. I. ^{[1
]}

Ali, A. ^{[1
]}

Sultana, Y. ^{[1
]}

Aqil, M. ^{[1
]}

Shakeel, F. ^{[2
]}

机构：

[1] Jamia Hamdard, Dept Pharmaceut, Fac Pharm, New Delhi 110062, India

[2] Al Arab Med Univ, Fac Pharm, Dept Pharmaceut, Benghazi, Libya

来源：

PHARMAZIE | 2010年 / 65卷 / 09期

关键词：

IN-VITRO; MECHANISM;

D O I：

10.1691/ph.2010.0083

中图分类号：

R914 [药物化学];

学科分类号：

100705 [微生物与生化药学];

摘要：

Monolithic transdermal therapeutic systems (US) were developed for sustained antihypertensive effect of losartan potassium using the polymers Eudragit E 100 and polyvinyl pyrrolidone VA 64. The developed formulations (polymeric films) were evaluated for physical characteristics, ex vivo (histopathology) and in vivo (pharmacokinetic studies). Pharmacokinetic parameters, such as C-max t(max) and AUC were estimated. The transdermal formulation in the present study was found to enhance the relative bioavailability of losartan potassium by 2.2 times with reference to an oral delivery. The increased bioavailability might be due to elimination of hepatic first pass metabolism. Thus, the transdermal formulation F3E with polymeric composition of Eudragit E 100 and polyvinyl pyrrolidone VA 64 (5:3) was found to provide prolonged

引用

页码：679 / 682

页数：4

共 9 条

[1]

Ansari M., 2004, IJPT, V3, P21

[2]

AQIL M, 2004, ETHIOP PHARM J, V53, P119

[3]

Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt [J].

Arora, P ;

Mukherjee, B .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (09) :2076-2089

[4]

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[5]

Efficacy and irritancy of enhancers on the in-vitro and in-vivo percutaneous absorption of curcumin [J].

Fang, JY ;

Hung, CF ;

Chiu, HC ;

Wang, JJ ;

Chan, TF .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (05) :593-601

[6]

Examination of the mechanism of oleic acid-induced percutaneous penetration enhancement: an ultrastructural study [J].

Jiang, SJ ;

Zhou, XJ .

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2003, 26 (01) :66-68

[7]

Simultaneous determination of losartan potassium and hydrochlorothiazide from tablets and human serum by RP-HPLC [J].

Özkan, SA .

JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2001, 24 (15) :2337-2346

[8]

Shakeel F, 2008, J DRUG TARGET, V16, P733, DOI [10.1080/10611860802473402, 10.1080/10611860802473402 ]

[9]

Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation [J].

Thakur, Reena ;

Anwer, Md Khalid ;

Shams, Mohammad S. ;

Ali, Asgar ;

Khar, Roop K. ;

Shakeel, Faiyaz ;

Taha, Ehab I. .

JOURNAL OF DRUG TARGETING, 2009, 17 (06) :442-449

← 1 →